TY - JOUR
T1 - Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility
AU - Chou, Sunwen
AU - Bowlin, Terry L.
PY - 2011/1
Y1 - 2011/1
N2 - Among the 7 most common UL97 mutations encountered in ganciclovir-resistant clinical cytomegalovirus isolates, the associated cyclopropavir cross-resistance varies from insignificant (L595S) to substantial (M460I and H520Q) as determined by recombinant phenotyping. Mutations M460I and H520Q were preferentially selected in vitro under cyclopropavir and conferred 12- to 20-fold increases in 50% effective concentration (EC50) values, while M460V, C592G, A594V, and C603W conferred 3- to 5-fold increases. Uncommon mutations M460T and C603R increased cyclopropavir EC50s by 8- to 10-fold.
AB - Among the 7 most common UL97 mutations encountered in ganciclovir-resistant clinical cytomegalovirus isolates, the associated cyclopropavir cross-resistance varies from insignificant (L595S) to substantial (M460I and H520Q) as determined by recombinant phenotyping. Mutations M460I and H520Q were preferentially selected in vitro under cyclopropavir and conferred 12- to 20-fold increases in 50% effective concentration (EC50) values, while M460V, C592G, A594V, and C603W conferred 3- to 5-fold increases. Uncommon mutations M460T and C603R increased cyclopropavir EC50s by 8- to 10-fold.
UR - http://www.scopus.com/inward/record.url?scp=78650664958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650664958&partnerID=8YFLogxK
U2 - 10.1128/AAC.01259-10
DO - 10.1128/AAC.01259-10
M3 - Article
C2 - 21041510
AN - SCOPUS:78650664958
SN - 0066-4804
VL - 55
SP - 382
EP - 384
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 1
ER -